Substrate reduction therapy in mouse models of the glycosphingolipidoses

Frances M Platt, Mylvaganam Jeyakumar, Ulrika Andersson, Tanya Heare, Raymond A Dwek, Terry D Butters, Frances M Platt, Mylvaganam Jeyakumar, Ulrika Andersson, Tanya Heare, Raymond A Dwek, Terry D Butters

Abstract

Substrate reduction therapy uses small molecules to slow the rate of glycolipid biosynthesis. One of these drugs, N-butyldeoxynojirimycin (NB-DNJ), shows efficacy in mouse models of Tay-Sachs, Sandhoff and Fabry diseases. This offers the prospect that NB-DNJ may be of therapeutic benefit, at least in the juvenile and adult onset variants of these disorders. The infantile onset variants will require an additional enzyme-augmenting modality if the pathology is to be significantly improved. A second drug, N-butyldeoxyglactonojirimycin, looks very promising for treating storage diseases with neurological involvement as high systemic dosing is achievable without any side-effects.

References

    1. Nat Rev Drug Discov. 2002 Jan;1(1):65-75
    1. Trans Assoc Am Physicians. 1991;104:258-64
    1. J Clin Invest. 1998 May 1;101(9):1881-8
    1. Glycoconj J. 1998 Jul;15(7):627-36
    1. Expert Opin Biol Ther. 2001 Sep;1(5):857-67
    1. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):915-9
    1. Blood. 2001 Jan 1;97(1):327-9
    1. N Engl J Med. 1974 Oct 31;291(18):929-31
    1. Hum Mol Genet. 1996 Jan;5(1):1-14
    1. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2503-8
    1. J Inherit Metab Dis. 1998 Aug;21(5):540-7
    1. Chem Rev. 2000 Dec 13;100(12):4683-96
    1. Hum Mol Genet. 1997 Feb;6(2):205-11
    1. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):863-8
    1. J Biol Chem. 1994 Mar 18;269(11):8362-5
    1. J Clin Invest. 2000 Jun;105(11):1563-71
    1. Science. 1997 Apr 18;276(5311):428-31
    1. Transplantation. 1995 Mar 27;59(6):864-70
    1. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):921-5
    1. Trends Cell Biol. 1998 May;8(5):198-202
    1. Nat Genet. 1995 Oct;11(2):170-6
    1. J Biochem. 1992 Feb;111(2):191-6
    1. Am J Physiol. 1998 Feb;274(2 Pt 1):C319-32
    1. Annu Rev Biochem. 1991;60:257-80
    1. Biochem Pharmacol. 2000 Apr 1;59(7):821-9
    1. Lancet. 2001 Aug 25;358(9282):601-3
    1. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):847-61
    1. Proc Natl Acad Sci U S A. 1999 May 25;96(11):6388-93
    1. JAMA. 1999 Jan 20;281(3):249-54
    1. Cell. 2001 Aug 24;106(4):403-11
    1. J Lipid Res. 1987 May;28(5):565-71
    1. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):927-45
    1. Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9975-9
    1. Adv Lipid Res. 1993;26:119-42
    1. J Biol Chem. 1993 Mar 15;268(8):5341-4
    1. Chem Phys Lipids. 1980 Apr;26(3):265-78
    1. J Neuropathol Exp Neurol. 1975 May;34(3):249-62
    1. Brain. 2003 Apr;126(Pt 4):974-87
    1. Clin Chim Acta. 1997 Oct 9;266(1):51-61
    1. Trends Neurosci. 1998 Mar;21(3):126-30
    1. FEBS Lett. 1994 Jun 6;346(1):103-7
    1. Trends Cell Biol. 1996 Mar;6(3):98-103
    1. Nature. 1992 Jun 4;357(6377):407-10
    1. Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9142-7
    1. Mamm Genome. 1995 Dec;6(12):844-9
    1. Brain Pathol. 1998 Jan;8(1):195-215
    1. Neurobiol Dis. 2002 Aug;10(3):201-10
    1. Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2540-4

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj